23 Biotechnology Stocks to Sell Now

23 Biotechnology Stocks to Sell Now

This week, the ratings of 23 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Shire PLC Sponsored ADR’s (SHPG) rating worsens to a D from the company’s C rating a week ago. Shire PLC Sponsored ADR a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of SHPG stock.

Alexion Pharmaceuticals, Inc. (ALXN) slips from a D to a F this week. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

Slipping from a D to a F rating, Vertex Pharmaceuticals Incorporated (VRTX) takes a hit this week. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

Radius Health Inc (RDUS) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RDUS stock.

Ophthotech Corp. (OPHT) declines this week from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

This is a rough week for Loxo Oncology Inc (LOXO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

La Jolla Pharmaceutical Company (LJPC) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Otonomy, Inc. (OTIC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OTIC stock.

This week, Aduro BioTech, Inc. (ADRO) drops from a D to a F rating. For more information, get Portfolio Grader’s complete analysis of ADRO stock.

Aquinox Pharmaceuticals, Inc.’s (AQXP) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AQXP stock.

Inotek Pharmaceuticals Corporation (ITEK) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITEK stock.

Slipping from a C to a D rating, Achillion Pharmaceuticals, Inc. (ACHN) takes a hit this week. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Immune Design Corp. (IMDZ) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

Trevena, Inc. (TRVN) declines this week from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Vital Therapies, Inc.’s (VTL) rating weakens this week, dropping to a D versus last week’s B. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.

This week, OvaScience, Inc.’s (OVAS) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OVAS stock.

This is a rough week for Progenics Pharmaceuticals, Inc. (PGNX). The company’s rating falls to D from the previous week’s B. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This week, Intec Pharma Ltd (NTEC) drops from a C to a D rating. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NTEC stock.

Adaptimmune Therapeutics PLC Sponsored ADR (ADAP) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

Sunesis Pharmaceuticals, Inc. (SNSS) slips from a C to a D this week. Sunesis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SNSS stock.

Sangamo BioSciences, Inc. (SGMO) is having a tough week. The company’s rating falls from a D to a F. Sangamo BioSciences, Inc. is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

Celldex Therapeutics, Inc. (CLDX) earns a F this week, moving down from last week’s grade of D. Celldex Therapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

Regulus Therapeutics Inc.’s (RGLS) rating weakens this week, dropping to a F versus last week’s D. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/23-biotechnology-stocks-to-sell-now-4/.

©2019 InvestorPlace Media, LLC